Redeye has updated its estimates and provided commentary on the latest developments at Starbreeze.
Fjärde kvartalet utvecklades svagare än vad både Cell Impact och vi förväntade oss.
Under fjärde kvartalet levererade Botnia sin första guldtacka till kund.
Redeye leaves a comment following Alzinova’s announced study data form the high-dose phase Ib extens...
Sales +0%, EBIT +31% vs. ABGSCe, beat driven by FX revaluations Underlying EBIT in line with our exp...
Redeye return with a research update following BioArctic's Q4 report and recent events, including th...
Redeye provides an initial comment on the Q4 2024 report from Cheffelo, which was in line with annou...
Marimekko's fourth quarter revenue beat our estimates slightly due to strong development in Finland.
Redeye provides its initial take on Surgical Science’s Q4 2024 report, which featured decent top lin...
Sales -5% vs. cons, adj. EBITA -33% vs. cons Enters Norway with Habberstad acquisition Acquisition o...
Redeye provides an update following Truecaller’s Q4 2024 report, which exceeded expectations across ...
Redeye comments on Medivir's Q4 report of 2024. In the quarter, the phase IIa study of fostrox was c...
Redeye concludes that Smart Eye's Q4 2024 report was even better than it looked at first sight.
Redeye comments on Synact's Q4 report. Synact raised in total SEK65m from a combined rights and dire...
Strong Q4 organic growth and double-digit '25 target 10-8% EPS downgrades for '25e-'27e Trading well...
Redeye comments on the evening’s news regarding Integrum’s strategic shift for accelerating OPRA com...
24% organic sales growth y-o-y Improved gross margin due to pricing and mix Opex flat y-o-y leads to...
Earnings growth to pick up in 2025 EBIT raised by 3% for 2025e 2025e-26e EV/EBIT of 4x with easy com...
Justerat för jämförelsestörande poster kom rapporten in över vår prognos.
Redeye notes that the underlying Q4 figures came in stronger than anticipated, primarily due to bett...
